SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders. It has applied advanced genetic engineering to develop transchromosomic for hyperimmunization and plasma collection, as well as develops product to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 2b clinical trials in delaying the onset or progression of type 1. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida. Show more

Location: 777 W 41st St., Miami Beach, FL, 33140, United States | Website: https://www.sabbiotherapeutics.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

24.15M

52 Wk Range

$1.00 - $5.01

Previous Close

$2.50

Open

$2.44

Volume

70,740

Day Range

$2.42 - $2.73

Enterprise Value

10.24M

Cash

12.85M

Avg Qtr Burn

-7.835M

Insider Ownership

21.02%

Institutional Own.

23.99%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date